Financial reports
Current reports
8-K
Results of Operations and Financial Condition
25 Apr 24
8-K
Other Events
9 Apr 24
8-K
Regulation FD Disclosure
5 Apr 24
8-K/A
Financial Statements and Exhibits
1 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
1 Apr 24
8-K
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
20 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Mar 24
8-K
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
5 Mar 24
8-K
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple
5 Feb 24
Registration and prospectus
S-8
Registration of securities for employees
5 Jan 24
S-8
Registration of securities for employees
17 Mar 23
424B5
Prospectus supplement for primary offering
1 Mar 23
424B5
Prospectus supplement for primary offering
28 Feb 23
424B5
Prospectus supplement for primary offering
18 Nov 22
S-3
Shelf registration
7 Nov 22
POS AM
Prospectus update (post-effective amendment)
1 Nov 22
424B3
Prospectus supplement
27 Oct 22
424B3
Prospectus supplement
7 Sep 22
424B3
Prospectus supplement
10 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Mar 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
Other
UPLOAD
Letter from SEC
4 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
UPLOAD
Letter from SEC
22 Nov 23
CT ORDER
Confidential treatment order
12 Dec 22
EFFECT
Notice of effectiveness
21 Nov 22
CORRESP
Correspondence with SEC
16 Nov 22
UPLOAD
Letter from SEC
10 Nov 22
EFFECT
Notice of effectiveness
4 Nov 22
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
4 May 22